Delort Sergio, Marchi Evaldo, Corrêa Marcos Antônio
Graduate program of the Faculdade de Medicina de Jundiaí (FMJ) - Jundiaí (SP), Brazil.
Departament of Thoracic Surgery of the Faculdade de Medicina de Jundiaí (FMJ) - Jundiaí (SP), Brazil.
An Bras Dermatol. 2017 Mar-Apr;92(2):217-220. doi: 10.1590/abd1806-4841.201755126.
Hyperhidrosis is the excessive production of sweating, which can be primary and focal or secondary to various pathologies. The exact cause of primary focal hyperhidrosis is still unknown, although a genetic basis is recognized, and its prevalence varies from 1% to 2.8%. The most affected sites are the armpits, palms, soles and face. It causes much discomfort, affects the quality of life, and is estimated to be undervalued by health professionals. Many treatment options are proposed, both clinical and surgical. The aim of this review is to focus on the treatment of hyperhidrosis with oxybutynin, an anticholinergic drug originally used to control overactive bladder.
多汗症是指出汗过多,可分为原发性局灶性多汗症或继发于各种病理状况。原发性局灶性多汗症的确切病因尚不清楚,尽管已确认存在遗传基础,其患病率在1111%至2.8%之间。受影响最严重的部位是腋窝、手掌、脚底和面部。它会引起诸多不适,影响生活质量,而且据估计未得到医疗专业人员的充分重视。目前提出了许多临床和手术治疗方案。本综述的目的是聚焦于用奥昔布宁治疗多汗症,奥昔布宁是一种最初用于控制膀胱过度活动症的抗胆碱能药物。